Core Viewpoint - The article discusses the ongoing dispute between Jiangsu Wuzhong and Aimeike over the exclusive distribution rights of the AestheFill product, a popular imported facial filler, highlighting the implications for both companies amid a competitive medical aesthetics market [2][4][44]. Group 1: Dispute Overview - The dispute involves Jiangsu Wuzhong and Aimeike regarding the exclusive distribution rights of AestheFill, with Aimeike's subsidiary REGEN Biotech seeking to terminate the agreement with Jiangsu Wuzhong's subsidiary [4][10]. - Jiangsu Wuzhong claims that the exclusive distribution rights are valid until August 28, 2032, and that the agreement has not been violated [28][40]. - The conflict arises from allegations of business transfer violations and regulatory issues faced by Jiangsu Wuzhong, which could impact the reputation of AestheFill in the Chinese market [10][11]. Group 2: Financial Implications - Jiangsu Wuzhong's stock price fell to a 60-day low following the dispute, while Aimeike's stock price increased, indicating market reactions to the news [6][30]. - AestheFill significantly contributed to Jiangsu Wuzhong's financial turnaround, with sales revenue of approximately 326.41 million yuan in 2024, accounting for 20.42% of the company's total revenue [37][33]. - Aimeike's revenue from its injection products, including AestheFill, was approximately 3.0257 billion yuan in 2024, reflecting a 5.44% increase from the previous year [38]. Group 3: Market Context - The dispute highlights the intensifying competition in the medical aesthetics sector, with multiple players vying for market share, including established cosmetic companies and new entrants [44][46]. - The market has seen a rise in the number of approved facial fillers, with nine products currently available, indicating a growing demand and competition in the sector [45]. - The outcome of the dispute will likely influence the market positions and future prospects of both Jiangsu Wuzhong and Aimeike in the medical aesthetics industry [47].

个证券代码：600200 证券简称：*ST苏吴 公告编号：临2025-076 江苏吴中医药发展股份有限公司 股票交易异常波动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要风险提示： 江苏吴中医药发展股份有限公司（以下简称"公司"）股票连续三个交 易日内收盘价格跌幅偏离值累计超过 12%，属于股票交易异常波动的情形。 2025 年 7 月 13 日，公司收到中国证券监督管理委员会（以下简称"中 国证监会"）下发的《行政处罚事先告知书》（处罚字〔2025〕58 号），具体 内容详见公司于 2025 年 7 月 14 日披露的《关于收到中国证券监督管理委员会< 行政处罚事先告知书>的公告》（公告编号：临 2025-064）。公司股票已于 2025 年 7 月 14 日起被叠加实施退市风险警示，如根据中国证监会正式的处罚决定书 结论，公司触及重大违法强制退市情形，公司股票将被终止上市。敬请广大投资 者关注后续公告并注意投资风险。 公司 2024 年度财务报告被年审机构出具无法表示意见，触及《上海证券 交易所股票上市规则》 ...

New Stock Issuance - Multiple companies are scheduled for new stock issuance on July 24, 2025, including *ST Zitian (300280) and ST Nanzhi (002305) [1] - Significant announcements were made for companies like Guosheng Tang (300436) and Huayin Power (600744) on July 17 and July 15, respectively [1] Trading Alerts - Companies such as Gaoguan Min Explosive (002827) and Zhongyan Dadi (003001) have recent trading alerts as of July 24, 2025 [1] - A total of 50 companies have been flagged for abnormal trading fluctuations, indicating potential market volatility [2] Market Trends - The report highlights a trend of increased market activity with numerous companies announcing significant changes in stock status [1] - The presence of multiple *ST (Special Treatment) companies suggests heightened scrutiny and potential risk for investors [1] Regulatory Compliance - Companies are required to disclose significant announcements to ensure transparency in trading activities [1] - The report emphasizes the importance of monitoring announcements to assess market conditions and investment risks [1]

Group 1 - The controlling shareholder, Suzhou Wuzhong Investment Holding Co., Ltd., holds 122,795,762 shares of Jiangsu Wuzhong Pharmaceutical Development Co., Ltd., accounting for 17.24% of the total share capital [2] - As of the announcement date, all shares held by the controlling shareholder are under pledge, judicial marking, judicial freezing, or pending freezing status [2][3] - The company will actively and prudently address the risks associated with stock pledges and freezes [3] Group 2 - The company will further verify the situation regarding the controlling shareholder's shares being judicially frozen and marked, and will continuously monitor the resolution of debt risks [3]

Group 1 - Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. (*ST Suwu) faced its eighth consecutive trading halt on July 23 due to significant operational challenges stemming from a contract termination with its subsidiary REGEN Biotech, Inc. [1] - REGEN Biotech announced on July 18 that it had sent a termination notice to Datuo Medical (Shanghai) Co., Ltd., which will result in the loss of exclusive distribution rights for the AestheFill product in mainland China [1] - The termination of the distribution agreement is expected to lead to a substantial decrease in revenue and profit for *ST Suwu's medical aesthetics segment in the second half of 2025 [1] Group 2 - On July 13, *ST Suwu received a notice from the China Securities Regulatory Commission (CSRC) regarding administrative penalties for inflating revenue, costs, and profits, with false records in annual reports from 2020 to 2023 [2] - The CSRC plans to impose a fine of 10 million yuan and issue warnings to related personnel, which may trigger mandatory delisting due to serious violations of the Shanghai Stock Exchange listing rules [2] - Following the CSRC's notice, *ST Suwu has been placed under a delisting risk warning by the Shanghai Stock Exchange since July 14 [2]

证券代码：600200 证券简称：*ST 苏吴 公告编号：临 江苏吴中医药发展股份有限公司 关于公司控股股东所持股份被司法冻结及司法标记的公告 2025-075 ? 截至本公告披露日，江苏吴中医药发展股份有限公司（以下简称"公司"） 控股股东苏州吴中投资控股有限公司（以下简称"控股股东"）持有公司 ? 截止目前，苏州吴中投资控股有限公司所持公司 122,795,762 股股份已全部 处于质押/司法标记/司法冻结/轮候冻结状态，请广大投资者注意投资风险。 统查询获悉，公司控股股东苏州吴中投资控股有限公司股份被司法冻结及司法标 记，具体情况如下： 一、本次股份被司法冻结和司法标记的基本情况 | 是否为 | | | | | | 冻结股份 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 冻结股份数量 | | 占其所持 | | 占公司 | | | | | | 总 | | | | 冻结申请 | | 冻结原 | | | | | 股东名称 | 控股股 | | | | | 是否为限 | | 冻结起始日 | 冻结 | | 到期日 ...

证券代码：600200 证券简称：*ST 苏吴 公告编号：临 2025-075 江苏吴中医药发展股份有限公司 关于公司控股股东所持股份被司法冻结及司法标记的公告 重要内容提示： 2025 年 7 月 23 日，公司通过中国证券登记结算有限责任公司上海分公司系 统查询获悉，公司控股股东苏州吴中投资控股有限公司股份被司法冻结及司法标 记，具体情况如下： 股东名称 是否为 控股股 东 冻结股份数量 （股） 占其所持 股份比例 占公司总 股本比例 冻结股份 是否为限 售股 冻结起始日 冻结到期日 冻结申请 人 冻结原 因 苏州吴中 投资控股 有限公司 是 122,795,762 100.00% 17.24% 否 2025-07-22 2028-07-21 江苏省苏 州市吴中 区人民法 院 司法冻 结/司 法标记 合计 122,795,762 100.00% 17.24% 一、本次股份被司法冻结和司法标记的基本情况 截至本公告披露日，江苏吴中医药发展股份有限公司（以下简称"公司"） 控股股东苏州吴中投资控股有限公司（以下简称"控股股东"）持有公司 122,795,762 股股份（均为无限售流通股），占公司总股本的 17 ...

New Stock Listings - Tech Source Group issued shares at a price of 10.88 CNY[1] - Shanda Power issued shares at a price of 14.66 CNY[1] Market Alerts - ST Zitian reported an equity date on July 21, 2025, with a link to the announcement[1] - Guangshengtang experienced severe abnormal fluctuations, with an announcement on July 17, 2025[1] - Huayin Power had an announcement on July 15, 2025, regarding market conditions[1] - Multiple companies including Shangwei New Materials, China Power Construction, and Jiangnan Chemical had announcements on July 23, 2025, regarding market activities[1] Abnormal Fluctuations - Companies such as ST Weier and ST Huadong reported significant fluctuations with announcements on July 21, 2025[2] - ST Jinyi and ST Yundong also reported abnormal fluctuations with announcements on July 17, 2025[2]

Core Viewpoint - Jiangsu Wuzhong is facing a significant setback due to the unilateral termination of its exclusive agency rights for the AestheFill product by Regen Biotech, which the company claims is an act of "malicious breach of contract" by its partner Aimeike [2][8]. Group 1: Agency Dispute - Jiangsu Wuzhong's subsidiary, Datuo Medical, received a termination notice from Regen Biotech regarding the exclusive distribution agreement for AestheFill [2][4]. - Regen Biotech alleges that Datuo Medical violated the agreement by transferring the agency rights to its parent company, Jiangsu Wuzhong Meisheng Biotechnology [4]. - The termination has led to Regen Biotech refunding payments for undelivered orders, further complicating Jiangsu Wuzhong's financial situation [2]. Group 2: Financial Impact - AestheFill, known as the "童颜针" (youthful needle), was a key product for Jiangsu Wuzhong, contributing significantly to its revenue and profit [13]. - In 2024, Jiangsu Wuzhong reported a revenue of 1.599 billion, with AestheFill sales accounting for 326 million, representing 20.42% of total revenue [13]. - The loss of exclusive agency rights could drastically reduce Jiangsu Wuzhong's income and profit, as AestheFill was a major driver of its financial recovery [13]. Group 3: Company Performance and Challenges - Jiangsu Wuzhong has struggled with poor financial performance, reporting losses in multiple years since 2018 [11]. - The company is also facing potential delisting due to significant financial irregularities, including inflated revenues and profits from 2020 to 2023 [14]. - The stock price of Jiangsu Wuzhong has declined by 4.71%, closing at 1.62 yuan, reflecting investor concerns over its financial stability [14].

Core Viewpoint - The termination of the exclusive distribution agreement between Regen and Datou Medical is expected to significantly impact the sales and profits of *ST Suwu's medical aesthetics segment, as it will lose the exclusive rights to sell the AestheFill product in mainland China [1][4]. Group 1: Company Actions - On July 18, 2025, Regen sent a termination letter to Datou Medical, revoking its status as the exclusive distributor for the AestheFill product in mainland China [1][3]. - Following the termination, Datou Medical is prohibited from conducting any business activities as the exclusive distributor and will not be able to place any further orders with Regen [3][4]. - *ST Suwu has initiated a response plan upon receiving the termination letter and is prepared to take legal action if necessary to protect its rights [5]. Group 2: Financial Impact - In 2024, AestheFill generated sales revenue of 326 million yuan, accounting for 20.42% of *ST Suwu's total revenue, with a gross profit of 269 million yuan, representing 34.80% of the company's gross profit [4]. - In the first quarter of 2025, AestheFill sales revenue reached 113 million yuan, making up 35.55% of the company's revenue, with a gross profit of approximately 92.44 million yuan, which is 45.77% of the total gross profit [4]. - The loss of exclusive distribution rights is expected to lead to a significant decline in revenue and profit for the medical aesthetics segment in the second half of 2025 [4]. Group 3: Background Information - The exclusive distribution agreement was originally signed between REGEN and Datou Medical, with the latter acquiring exclusive rights to AestheFill in mainland China in August 2022 [2]. - The agreement was violated by Datou Medical, which allegedly transferred the exclusive distribution business to its controlling shareholder, Jiangsu Wuzhong Meisheng Biotechnology Co., Ltd., leading to the termination [3].